PWG
REGN icon

Portside Wealth Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Portside Wealth Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
2,159
+181
+9% +$123K 0.16% 147
2026
Q1 		$1.53M Buy
1,978
+192
+11% +$147K 0.21% 118
2025
Q4 		$1.38M Buy
1,786
+239
+15% +$162K 0.19% 125
2025
Q3 		$870K Buy
1,547
+225
+17% +$127K 0.12% 180
2025
Q2 		$694K Buy
1,322
+208
+19% +$116K 0.1% 202
2025
Q1 		$707K Buy
1,114
+338
+44% +$232K 0.12% 190
2024
Q4 		$553K Buy
776
+52
+7% +$43.6K 0.09% 214
2024
Q3 		$761K Buy
724
+93
+15% +$103K 0.13% 170
2024
Q2 		$663K Buy
631
+32
+5% +$31K 0.13% 171
2024
Q1 		$577K Buy
599
+53
+10% +$50.4K 0.11% 196
2023
Q4 		$480K Buy
546
+58
+12% +$47.8K 0.09% 216
2023
Q3 		$401K Buy
488
+90
+23% +$70.7K 0.08% 219
2023
Q2 		$286K Buy
+398
New +$307K 0.05% 264

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Portside Wealth Group's REGN Position: Q2 2026 in Review

Portside Wealth Group increased its Regeneron Pharmaceuticals (REGN) stake by 9.2% in Q2 2026, buying an estimated $123K and bringing the position to 2,159 shares worth $1.35M. The position accounts for 0.16% of the portfolio, ranked #147.

Portside Wealth Group first reported a position in REGN in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.53M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Portside Wealth Group held 2,159 shares of Regeneron Pharmaceuticals worth $1.35M as of Q2 2026.
  • Portside Wealth Group bought 181 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $123K.
  • Regeneron Pharmaceuticals made up 0.16% of Portside Wealth Group's portfolio in Q2 2026, its #147 holding.
  • Portside Wealth Group first reported a position in Regeneron Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Portside Wealth Group's Regeneron Pharmaceuticals position peaked at $1.53M in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Portside Wealth Group's 13F filing for Q2 2026, filed 14 Jul 2026.